Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Research Article
3 May 2018

Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population

Authors: Kruti Joshi [email protected], Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar, and Brandon SuehsAuthor Info & Affiliations
Volume 7, Number 8
https://doi.org/10.2217/cer-2018-0003
PDFFormats

Abstract

Aim: To compare adherence, healthcare utilization and costs among real world, Medicare-eligible patients with schizophrenia using long-acting injectable paliperidone palmitate (PP) versus oral atypical antipsychotics. Patients & methods: Historical cohort study used Medicare Advantage claims data. Inverse probability of treatment weighting was applied to adjust for baseline differences. 12-month adherence, healthcare utilization and costs were compared. Results: Patients using PP were more adherent (proportion of days covered ≥0.8; 48.1 vs 32.6%; p < 0.001), had lower odds of hospitalization (odds ratio [OR]: 0.81; 95% CI: 0.68–0.96) and lower medical costs ($11,095; 95% CI: $10,374–11,867 vs $15,551; 95% CI: $14,584–16,583), but higher pharmacy costs ($14,787; 95% CI: $14,117–15,488 vs $5781; 95% CI: $5530–6043). Conclusion: Compared with patients using oral atypical antipsychotics, PP had lower hospitalizations and medical costs with greater medication adherence accompanied by higher pharmacy costs.

Supplementary Material

File (supplementary_table_1.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr. Q. 73(4), 297–311 (2002).
PubMed
Google Scholar
2.
Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat. Outcome Meas. 5, 43–62 (2014).
PubMed
Google Scholar
• Provides a good overall review of the problem of adherence with antipsychotic medications, its assessment and interventions to improve adherence.
3.
Lang K, Meyers JL, Korn JR et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr. Serv. 61(12), 1239–1247 (2010).
PubMed
Google Scholar
4.
Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161(4), 692–699 (2004).
PubMed
Google Scholar
5.
Cloutier M, Aigbogun MS, Guerin A et al. The economic burden of schizophrenia in the United States in 2013. J. Clin. Psychiatry 77(6), 764–771 (2016).
PubMed
Google Scholar
•• Estimates direct and nondirect healthcare costs, as well as nonhealthcare costs attributable to schizophrenia. Excess costs for schizophrenia were attributable to unemployment, productivity loss due to caregiving, and direct healthcare costs.
6.
Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(2 Suppl.), 1–56 (2004).
PubMed
Google Scholar
7.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT). The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr. Bull. 36(1), 94–103 (2009).
PubMed
Google Scholar
8.
Barnes T; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 25(5), 567–620 (2011).
PubMed
Google Scholar
9.
Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br. J. Psychiatry Suppl. 52, S1–S4 (2009).
PubMed
Google Scholar
10.
Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer. Adherence 7, 1171–1180 (2013).
PubMed
Google Scholar
11.
Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals, Inc. (June 2017). www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf
Google Scholar
12.
US Department of Health and Human Services. What is the difference between Medicare and Medicaid? www.hhs.gov/answers/medicare-and-medicaid/what-is-the-difference-between-medicare-medicaid/index.html
Google Scholar
13.
US Department of Veterans Affairs. About VHA. www.va.gov/health/aboutVHA.asp
Google Scholar
14.
Pesa JA, Muser E, Montejano LB, Smith DM, Meyers OI. Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes 2(4), 377–385 (2015).
PubMed
Google Scholar
• As in this study, paliperidone palmitate (PP) was associated with greater adherence, lower medical costs, but higher pharmacy costs relative to treatment with oral atypical antipsychotics.
15.
Lafeuille MH, Grittner AM, Fortier J et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am. J. Health Syst. Pharm. 72(5), 378–389 (2015).
PubMed
Google Scholar
•• The authors found lower rehospitalization rates and lower medical costs for patients taking PP versus patients taking oral atypical antipsychotics.
16.
Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J. Med. Econ. 18(5), 357–365 (2015).
PubMed
Google Scholar
17.
Xiao Y, Muser E, Lafeuille MH et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J. Comp. Effectiveness Res. 4(6), 579–592 (2015).
PubMed
Google Scholar
18.
Xiao Y, Muser E, Fu DJ et al. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. Curr. Med. Res. Opin. 32(4), 759–769 (2016).
PubMed
Google Scholar
19.
Young-Xu Y, Duh MS, Muser E et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J. Clin. Psychiatry 77(10), e1332–e1341 (2016).
PubMed
Google Scholar
•• Treatment with PP was associated with significantly reduced inpatient hospitalization and higher mental health intensive case management. Higher pharmacy and outpatient costs with PP treatment were offset by lower inpatient stay costs, resulting in total overall cost savings with PP relative to oral agents.
20.
Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care 43(11), 1130–1139 (2005).
PubMed
Google Scholar
21.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661–3679 (2015).
PubMed
Google Scholar
22.
Roberto P, Brandt N, Onukwugha E et al. Adherence to antipsychotic therapy: association with hospitalization and Medicare spending among part D enrollees with schizophrenia. Psychiatr. Serv. 68(11), 1185–1188 (2017).
PubMed
Google Scholar
23.
Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J. Manag. Care Spec. Pharm. 21(9), 754–768 (2015).
PubMed
Google Scholar
• This claims-based analysis of posthospitalization and rehospitalization outcomes in Medicaid patients shows lower rates of nonadherence, continuous 60-day gap in medication coverage, and rehospitalization in patients using long-acting injectables (LAIs) compared with oral medication; second-generation LAIs conferred the greatest benefits. PP was the only LAI associated with a statistically significant lower risk of rehospitalization compared with oral medication.
24.
Fleischhacker WW, Gopal S, Lane R et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int. J. Neuropsychopharmacol. 15(1), 107–118 (2012).
PubMed
Google Scholar
25.
McEvoy JP, Byerly M, Hamer RM et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311(19), 1978–1987 (2014).
PubMed
Google Scholar
26.
Rosenheck RA, Leslie DL, Sint KJ et al. Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia. Psychiatr. Serv. 67(10), 1124–1130 (2016).
PubMed
Google Scholar
27.
NAMI Utah. Preferred drug list. http://namiut.org/images/PDL_-_Research_Summary__NAMI_Utah__Visuals_2016.pdf
Google Scholar
• Data from the National Alliance on Mental Illness, Utah, outlining the consequences of access restrictions to mental health medications.
28.
Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ. 23(3), 359–373 (2014).
PubMed
Google Scholar
•• A study of antipsychotic drug use in Medicaid patients with schizophrenia found that patients receiving generic medications had significantly higher numbers of overall and schizophrenia-related hospitalizations within 1 year.
|